Secnidazole
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Secnidazole: From Bacterial Vaginosis to Vaginal Discharge
One-Sentence Summary
Secnidazole is a 5-nitroimidazole antimicrobial/antiprotozoal agent, marketed internationally (as Solosec®) for bacterial vaginosis and trichomoniasis, but not yet marketed in Taiwan. The TxGNN model’s best-supported prediction is that Secnidazole effectively resolves Vaginal Discharge, the hallmark symptom of bacterial vaginosis/trichomoniasis, with 5 clinical trials (including 2 pivotal Phase 3 RCTs) and 17 publications currently supporting this direction.
This evidence pack contains 7 TxGNN-predicted indications for secnidazole. This report focuses on Vaginal Discharge (the candidate with the strongest, decision-ready evidence — L1, Proceed with Guardrails). A closely related, already-confirmed indication (trichomonal vulvovaginitis) and several low-plausibility, unsupported predictions (postmenopausal atrophic vaginitis, vulvar neoplasm, vulvar ulceration, vaginal leukoplakia) are addressed in the Conclusion.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not licensed in Taiwan; internationally approved for bacterial vaginosis (Solosec®, US FDA 2017) |
| Predicted New Indication | Vaginal Discharge (bacterial vaginosis / trichomoniasis symptom) |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L1 |
| Market Status (Taiwan) | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
The formal DrugBank mechanism-of-action field for secnidazole is currently a data gap. However, based on its established pharmacological class, secnidazole is a second-generation 5-nitroimidazole (same family as metronidazole and tinidazole, but with a longer half-life of ~17 hours). After reduction by anaerobic bacterial or protozoal nitroreductases, it generates reactive intermediates that damage pathogen DNA, giving it activity against anaerobic bacteria (e.g., Gardnerella vaginalis) and protozoa (Trichomonas vaginalis).
Abnormal vaginal discharge is the defining clinical symptom of bacterial vaginosis and trichomoniasis — the two conditions secnidazole is already approved to treat internationally. The TxGNN prediction therefore does not represent a novel biological mechanism, but rather links the drug to the downstream symptom of an indication it already treats. This makes the mechanistic rationale direct and well-established, rather than speculative.
A closely related prediction in the same evidence pack, trichomonal vulvovaginitis, is even stronger in this respect: the FDA approved Solosec® for trichomoniasis in adult women in 2021 based on a pivotal Phase 3 RCT (PMID 33768237). From a global regulatory standpoint this is a confirmed indication, not merely a model prediction; it only appears here because secnidazole is not yet registered in Taiwan.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03935217 | Phase 3 | Completed | 147 | Randomized, double-blind, placebo-controlled pivotal trial of single-dose Solosec® granules; key registration evidence for symptomatic relief (incl. discharge) |
| NCT02147899 | Phase 2 | Completed | 215 | Randomized, double-blind, placebo-controlled trial of secnidazole (SYM-1219) for BV; symptom endpoints included discharge |
| NCT02111629 | Phase 3 | Completed | 118 | Secnidazole + fluconazole combination for symptomatic vaginal discharge in mixed BV/Candida infections |
| NCT05033743 | Phase 2/3 | Completed | 24 | Pilot study of weekly secnidazole granules for suppression of recurrent BV over 18 weeks |
| NCT03937869 | Phase 4 | Completed | 40 | Post-marketing safety study of single-dose Solosec® 2g in adolescent girls with BV |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28867602 | 2017 | RCT (Phase 3) | Am J Obstet Gynecol | Pivotal double-blind, placebo-controlled trial establishing efficacy/safety of single-dose secnidazole 2g granules for BV |
| 20885970 | 2010 | RCT (Phase 3) | Infect Dis Obstet Gynecol | Multicenter double-blind, double-dummy noninferiority trial: secnidazole vs. metronidazole for BV |
| 22529484 | 2012 | Comparative RCT | Indian J Pharmacol | Compared single-dose metronidazole, tinidazole, secnidazole, and ornidazole cure rates in BV |
| 31129560 | 2019 | Systematic Review/Meta-analysis | Eur J Obstet Gynecol Reprod Biol | Pooled efficacy/safety of single-dose oral secnidazole 2g for BV |
| 39463760 | 2024 | Systematic Review/Network Meta-analysis | Front Cell Infect Microbiol | Comparative efficacy/safety of multiple drugs (incl. secnidazole) for BV |
| 29323627 | 2018 | Phase 3, Open-label | J Womens Health | Safety of single-dose secnidazole 2g granules in US women/adolescents with BV |
| 29132478 | 2017 | RCT | J Coll Physicians Surg Pak | Compared vaginal clindamycin vs. single oral-dose secnidazole for symptomatic BV |
| 15733882 | 2005 | Clinical Study | Int J Gynaecol Obstet | Evaluated whether low-dose (1g) secnidazole cures BV |
| 31499057 | 2020 | Review | Am J Obstet Gynecol | Discharge/malodor as the hallmark BV symptom; treatment reduces post-surgical infection risk |
| 9617020 | 1998 | Comparative Study | Ginecol Obstet Mex | Oral itraconazole + secnidazole vs. topical ovules for symptomatic vaginitis |
US Market Information
Secnidazole currently has no marketing authorization on file in Taiwan — this evidence pack records 0 licenses. Internationally, it is marketed as Solosec® (single-dose oral granule formulation), FDA-approved in the United States (2017 for bacterial vaginosis; 2021 for trichomoniasis). No Taiwan NDA data is available for tabulation.
Safety Considerations
No verified prescribing warnings, contraindications, or drug-drug interaction data are currently available for secnidazole in this evidence pack. This is flagged as a blocking data gap, meaning a formal safety pre-assessment cannot yet proceed. Please refer to the package insert (once a Taiwan label exists) or the current Solosec® US prescribing information for interim safety guidance.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two completed Phase 3 RCTs plus consistent supportive literature (including systematic reviews) establish that secnidazole resolves the discharge symptom of bacterial vaginosis, an indication already FDA-approved internationally. The main barriers are administrative (no Taiwan license) rather than scientific.
To proceed, the following is needed:
- Resolve the blocking safety data gap: obtain TFDA-equivalent prescribing warnings/contraindications (or adopt Solosec® US labeling as interim reference)
- Obtain formal DrugBank/MOA documentation to close the mechanism data gap
- Assess Taiwan regulatory pathway for market entry (new drug application vs. named-patient/off-label use)
- Confirm secnidazole’s independent contribution to vulvovaginal candidiasis efficacy (current evidence is confounded by fluconazole co-administration) — treat as a Research Question, not an actionable indication yet
- No further action needed on postmenopausal atrophic vaginitis, vulvar neoplasm, vulvar ulceration, or vaginal leukoplakia — these predictions have no supporting trials or literature and show no plausible mechanistic link to secnidazole’s antimicrobial/antiprotozoal activity; Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.